UHMK1 and hepatocellular carcinoma: Expression of UHMK1 was further verified as an event downstream of OXPHOS dysfunction because inactivation of complex I, complex III, complex IV and ATP synthase respectively by chemical inhibitors rotenone, antimycin A, azide and oligomycin all led to reduction of UHMK1 expression (Figure 6A,B and Figure S9), suggesting a potential role of UHMK1 expression for being as a biomarker of OXPHOS dysfunction, at least in hepatoma cells.